Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Mesa Laboratories (MLAB) Share Price

Media headlines about Mesa Laboratories (NASDAQ:MLAB) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mesa Laboratories earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.8858530054608 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:MLAB traded down $3.29 during mid-day trading on Friday, reaching $150.75. The stock had a trading volume of 29,130 shares, compared to its average volume of 14,234. The company has a current ratio of 2.37, a quick ratio of 1.64 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $582.76, a P/E ratio of 35.72 and a beta of 0.51. Mesa Laboratories has a 1 year low of $122.35 and a 1 year high of $169.80.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Monday, February 5th. The medical instruments supplier reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.77). The firm had revenue of $23.67 million during the quarter, compared to analysts’ expectations of $23.10 million. Mesa Laboratories had a positive return on equity of 9.20% and a negative net margin of 3.82%. research analysts forecast that Mesa Laboratories will post -1.18 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 15th. Investors of record on Thursday, May 31st will be given a $0.16 dividend. The ex-dividend date is Wednesday, May 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.42%. Mesa Laboratories’s dividend payout ratio is currently 15.17%.

Several brokerages have recently commented on MLAB. BidaskClub upgraded Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday. TheStreet downgraded Mesa Laboratories from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Zacks Investment Research downgraded Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, ValuEngine upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.

In related news, Director Robert V. Dwyer sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $144.01, for a total value of $720,050.00. Following the sale, the director now directly owns 68,521 shares in the company, valued at $9,867,709.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director John James Sullivan sold 4,000 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $138.00, for a total value of $552,000.00. Following the completion of the sale, the director now owns 72,248 shares in the company, valued at $9,970,224. The disclosure for this sale can be found here. Insiders sold 12,000 shares of company stock worth $1,668,860 over the last quarter. 15.70% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mesa-laboratories-mlab-share-price.html.

About Mesa Laboratories

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply